Jan. 30 at 7:21 PM
$HOTH
1) Analysts have a "Strong Buy" rating with a price target
$5.0.
2) The company maintains over
$9 million in cash and has explicitly stated they have no plans for further capital raises in 2026.They currently carry zero debt.
3) Hoth is using AI to model blood-brain barrier (BBB) permeability. NVIDIA’s tech is helping them determine if their therapeutic can actually reach the brain effectively.Hoth is using AI to analyze data targeting obesity and fatty liver disease.
4) The biggest win for
$HOTH is the interim data from its CLEER-001 trial. This drug helps cancer patients stay on their life-saving treatments (EGFR inhibitors) without stopping due to side effects.Essential "supportive care" therapy with a massive market.
5) Hoth Therapeutics filed an 8-K with the SEC on January 16, 2026, explicitly stating that management prepared these new materials for meetings with U.S. government officials
Strong candidate for potential federal grants or fast-track designations.
